- Home
- STG vs PRLD Comparison
STG vs PRLD Comparison
Compare STG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STG | PRLD |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 69.1M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STG | PRLD |
|---|---|---|
| Price | $6.20 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 4.8K | ★ 487.0K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $285,589,112.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.50 | ★ N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $4.28 | $0.61 |
| 52 Week High | $15.00 | $4.22 |
Technical Indicators
Market Signals| Indicator | STG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 75.44 |
| Support Level | $6.15 | $1.90 |
| Resistance Level | $6.48 | $2.38 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 67.62 | 93.83 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.